Therapeutic CD154 antibody for lupus: promise for the future?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 14617748.
- Also identified by PMC identifier 259140.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
Medical subject headings
- Antibodies, Monoclonal
- CD40 Ligand
- Immunization, Passive
- Lupus Erythematosus, Systemic